Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.
about
Is systems pharmacology ready to impact upon therapy development? A study on the cholesterol biosynthesis pathway.Cancer Therapy: Shooting for the Moon.Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis - an update.Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs.Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Driving Access to Medicines With a Totality of Evidence Mindset: An Opportunity for Clinical Pharmacology.Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.Revisiting Principles Behind Drug Clearance and Organ Extraction.Precision Pharmacotherapy Enables Precision Medicine.Challenges and Solutions for Future Pharmacy Practice in the Era of Precision MedicinePredicting the need for a reduced drug dose, at first prescriptionKey Components for Antibiotic Dose Optimization of Sepsis in Neonates and Infants
P2860
Q40046136-A19E4425-FC75-410D-842B-9C1556E1A303Q42336474-B381015A-3CA4-45B0-88AA-539AD993CDDFQ47273957-B567CDC7-07FD-4A71-8F00-811D27C7F703Q47384439-5F03A6F1-9490-4604-916D-F93F565B1357Q47602664-1B76D776-DAA6-418C-A31A-BF1F464D87BDQ47786666-A806C889-EA36-4871-89A0-7861496DDCE0Q48142540-035EEEAA-5FEF-457C-9A2E-9B924ECFFF83Q49171317-298592FF-E99C-4A36-BD23-3B3E893307BDQ49382344-03C08404-7378-46DE-8213-508A1B70F778Q50625597-B1DA5848-C9C4-42AB-A27E-ED2357A007F4Q52740994-E8F824DC-CB40-4906-A40A-8FCF565ED062Q53958606-3CF59B74-19F6-4E69-9872-5C67791C8EF2Q57171377-7A8D04F7-46E8-44A7-AC49-1ED995E9BBD4Q57805733-FDE8D5DC-2F06-4C52-983B-004D0EBB4AA1Q58699116-DE336099-1546-4B01-8676-66657C8CFBB7
P2860
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Why has model-informed precisi ...... and a roadmap for the future.
@en
type
label
Why has model-informed precisi ...... and a roadmap for the future.
@en
prefLabel
Why has model-informed precisi ...... and a roadmap for the future.
@en
P2093
P2860
P50
P356
P1476
Why has model-informed precisi ...... t and a roadmap for the future
@en
P2093
A Rostami-Hodjegan
A S Darwich
Caj Knibbe
J R Powell
J S Leeder
J S McCune
P2860
P304
P356
10.1002/CPT.659
P407
P577
2017-04-04T00:00:00Z